Evidence map›Paper›PMID 33144444›Full record

ArticleIn vivo (Athens, Greece)

Impact of Surgical Resection on Metachronous Metastases of Colorectal Cancer According to Tumor Doubling Time.

Hiroaki Miyake, Koji Murono, Kazushige Kawai, Hiroaki Nozawa, Harufumi Maki, Kiyoshi Hasegawa, Jun Nakajima, Soichiro Ishihara

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hiroaki MiyakeDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan MIYAKEH-SUR@h.u-tokyo.ac.jp.
Koji MuronoDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Kazushige KawaiDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Hiroaki NozawaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
Harufumi MakiHepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kiyoshi HasegawaHepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Jun NakajimaDepartment of Thoracic Surgery, The University of Tokyo, Tokyo, Japan.
Soichiro IshiharaDepartment of Surgical Oncology, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWe aimed to elucidate the prognostic impact of tumor doubling time (DT) and radical surgery when classified by DT in patients with metachronous liver, lung, or peritoneal metastases of colorectal cancer (CRC). PATIENTS AND

methodsWe reviewed the data of 1941 patients who underwent curative surgery for CRC and calculated DT for recurrences using computed tomography.

resultsShort DT was an independent prognostic risk factor in liver (p<0.001) and peritoneal (p=0.03) metastases. Survival was significantly better in patients who underwent surgery than in those who did not, both in short and long DT groups in any metastatic organ (p<0.01). Patients with long DT gained significantly better prognostic benefit from surgery than those with short DT in liver (p=0.01) and peritoneal (p=0.04) metastases.

conclusionSurgery is recommended for resectable metastases, especially in patients with liver and peritoneal metastases with long DT.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsHepatectomyHumansNeoplasm Recurrence, LocalPrognosisRetrospective StudiesColorectal carcinomadoubling timeprognosisrecurrencetumor growth rate

Identifiers

PMID33144444
PMCPMC7811596
OpenAlexW3097661046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.